HOME >> MEDICINE >> NEWS
Combined molecular-targeted and hormonal therapies offer promise in treating ovarian cancer

Houston May 08, 2007 -- A combination of molecular-targeted therapy and hormonal therapy may be the most promising area of research for those seeking an effective treatment for ovarian cancer, according to a new review in the International Journal of Gynecological Cancer.

"Several clinical trials have confirmed the role of hormone therapy in recurrent ovarian cancer treatment, especially in patients with low-grade tumors," says review author Dr. Siqing Fu, an assistant professor of oncology at the University of Texas at Houston. "However, more research is needed to determine whether combining molecular-targeted therapy with hormonal therapy would be a more effective option."

Ovarian cancer is the deadliest of gynecological cancers; approximately 70 percent of patients are diagnosed in the later stages, when the 5-year survival rate drops below 25 percent. Traditional chemotherapy has proven to be generally ineffective against recurrent ovarian cancer, which has led researchers to investigate novel treatments.

"While a cure is unlikely, the goals of treatment are to control tumor-related symptoms and to improve or maintain quality of life," says Dr. Fu. "After surveying the latest research, combined molecular-targeted and hormonal therapy offers the greatest promise in achieving these goals and therefore deserves further investigation."


'"/>

Contact: Sean Wagner
swagner@bos.blackwellpublishing.com
781-388-8550
Blackwell Publishing Ltd.
8-May-2007


Page: 1

Related medicine news :

1. Combined imaging approach may provide better identification of difficult-to-diagnose brain clots
2. Combined therapies may boost immune response and long-term protection against brain tumors
3. Combined liver-kidney transplant beneficial for patients with dual organ disease
4. Combined contrast enhanced MRI shows promise
5. Combined treatment cuts inflammatory cells in chronic obstructive pulmonary disease
6. Combined MRI and mammography more effective at detecting breast cancer in high-risk women
7. Nonhormonal drug reduces hot flashes in men treated for prostate cancer
8. Bulimia may result from hormonal imbalance
9. 1 in 5 early-stage breast cancer patients may not follow hormonal therapy plan
10. Genomic tests improve prediction of breast cancer response to chemotherapy, hormonal therapy
11. Some nonhormonal therapies may offer relief from hot flashes, but with possible adverse effects

Post Your Comments:
(Date:10/30/2014)... October 30, 2014 Graphics, coding, typography ... synonymous with the craft of web design and require ... Yet a simpler solution to create a website can ... videos, contact information, customer reviews and Facebook posts all ... "It is the next evolution of how a business ...
(Date:10/30/2014)... 2014 PreDiabetes Centers , the ... shoppers with a supply of sugardown®, a chewable ... post-meal blood sugar spikes. Learning how to control blood ... part of a diabetes prevention plan. , Shoppers who ... complimentary tube of sugardown. The offer expires November 30. ...
(Date:10/30/2014)... Tara Haelle HealthDay ... -- More than 100 genes have been identified that ... report. And researchers say they are on their ... may contribute to the disorder. Autism spectrum disorders ... and social difficulties and repetitive behaviors. An estimated one ...
(Date:10/30/2014)... Horse Sense & Sensitivity (HSS), ... needs individuals in the Jacksonville area, will be holding ... 10-2:00 p.m. at Bailey's Farm (2202 Bishop Estates Road). ... and is designed to raise awareness and funds to ... Round-Up is free. Ticket purchases will be required for ...
(Date:10/30/2014)... Carolina (PRWEB) October 30, 2014 The ... should be more vigorously exercised to help maintain better ... authored the book ‘Dementia Express: Lose Your Memory in ... uses counterintuitive reasoning and sometimes conflicting attitudes to help ... for the mind, a reader must decipher the hidden ...
Breaking Medicine News(10 mins):Health News:Facebook Websites In Thirty-Seconds 2Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2
(Date:10/31/2014)... Migranade, Inc. announced today the new migraine ... 36 million U.S. migraine sufferers November, 2014. The medicine ... actual cause of migraines and not just the symptoms. ... source Migranade is assured to be a game changer ... available at http://www.migranade.com and will soon hit ...
(Date:10/31/2014)... , Oct. 31, 2014  Isis Pharmaceuticals, Inc. ...  What: , Isis Pharmaceuticals, Third Quarter ... Friday, November 7 at 11:30 a.m. ET / 8:30 ... Live on the Internet. Simply log onto our website ... the live event, a replay of the webcast will ...
(Date:10/30/2014)... - Atlantic Canadians will save an estimated $560-million through ... provinces and territories and the generic pharmaceutical ... Generic Pharmaceutical Association (CGPA), said today. ... Atlantic Summit on Healthcare and Drug Cost Sustainability in ... by the Public Policy Forum and sponsored by the ...
Breaking Medicine Technology:Game Changing Migraine Medication To Be Available November 2014 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 3Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 2Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 3
Cached News: